The U.S. Food and Drug Administration issued a Complete Response Letter to Chicago’s Levo Therapeutics for the company’s New Drug Application for LV-101, which is being developed as a treatment for hyperphagia (excessive overeating), anxiousness and distress associated with Prader-Willi syndrome (PWS).
The U.S. Food and Drug Administration placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.
Denmark-based Saniona, which is focused on treating eating disorders and diseases of the central nervous system, co-founded a new company that is taking aim at the migraine market.
